Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?

Rheumatology (Oxford). 2016 Sep;55(9):1531-3. doi: 10.1093/rheumatology/kew010. Epub 2016 Mar 2.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adalimumab / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Azetidines / therapeutic use
  • Humans
  • Janus Kinases / antagonists & inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • United States

Substances

  • Antirheumatic Agents
  • Azetidines
  • Purines
  • Pyrazoles
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • Janus Kinases
  • Adalimumab
  • baricitinib